Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector

November 3, 2019

Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5; AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS)  on 11/6; Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML)  on 11/7 …. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12

Remember and never forget!

September 11, 2019

We should all observe (along with the NYSE) a minute of silence to honor the 9/11 terror attack victims and their families as well as the survivors and first-responders

Regenerative Medicine Earnings Scorecard - Q2/19 - to date

August 5, 2019

A scorecard of earnings of 45 covered  companies The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.